Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
8.450
-0.550 (-6.11%)
Streaming Delayed Price
Updated: 9:57 AM EDT, Aug 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
160,092
Open
8.360
Bid (Size)
8.430 (1)
Ask (Size)
8.460 (4)
Prev. Close
9.000
Today's Range
7.931 - 8.500
52wk Range
5.120 - 15.90
Shares Outstanding
60,717,176
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
August 02, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Expert Ratings For Travere Therapeutics
August 02, 2024
Via
Benzinga
Performance
YTD
-11.61%
-11.61%
1 Month
+7.10%
+7.10%
3 Month
+29.01%
+29.01%
6 Month
+2.30%
+2.30%
1 Year
-45.09%
-45.09%
More News
Read More
Travere Therapeutics Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
July 27, 2024
Via
Talk Markets
Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts
May 07, 2024
Via
Benzinga
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
April 17, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
March 13, 2024
Via
Benzinga
Travere Therapeutics to Report Second Quarter 2024 Financial Results
July 25, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
July 10, 2024
Via
Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
July 09, 2024
Via
Benzinga
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
July 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
May 09, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 06, 2024
Via
InvestorPlace
Travere Therapeutics Reports First Quarter 2024 Financial Results
May 06, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Report First Quarter 2024 Financial Results
April 29, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
April 04, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
April 03, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
March 11, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
February 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.